At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 56 enrolled
Drug / intervention
WN/DEN4-3'delta30 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1 Study of the Safety and Immunogenicity of West Nile/Dengue-4 3'delta30 Chimeric Virus Vaccine (WN/DEN4-3'delta30), a Live Attenuated Vaccine for West Nile Encephalitis
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Oct 22, 2004·Updated Jan 3, 2013
In Brief
A Phase 1 clinical trial evaluating WN/DEN4-3'delta30 and Placebo for West Nile Fever Encephalitis. Completed, enrolled 56 participants across 2 sites.
Detailed Summary
West Nile (WN) virus infection is an emerging disease; WN infection may lead to paralysis, coma, and death. The purpose of this study is to test the safety of and immune response to a WN vaccine in healthy adults. The vaccine is based on a live attenuated vaccine developed against dengue virus.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWest Nile Fever Encephalitis
CountriesUnited States
CollaboratorsJohns Hopkins Bloomberg School of Public Health
Timeline
Phase 1CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 2004
Enrollment StartFeb 2005
Primary CompletionApr 2005
TodayJul 2026
First PostedOct 22, 2004
Enrollment StartFeb 1, 2005
Primary CompletionApr 1, 2005
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 21.7 years ago
Interventions
WN/DEN4-3'delta30biological
Live attenuated WN/DEN4-3'delta30 vaccine (one of three doses)
Placebobiological
Placebo for WN/DEN4-3'delta30 vaccine